Roche's ( OTCQX: RHHBY ) Lebrikizumab injection significantly lowered the rate of asthma attacks and improved lung function in a Phase IIb trial of patients
The Italian Competition Authority has fined Novartis ( NVS ) €92M and Roche ( OTCQX: RHHBY ) €90.5M for forming a cartel to push doctors to prescribe their jointly marketed and more expensive Lucentis therapy to treat
top nine names here are drugmakers, including Roche Holding RHHBY , owned by nearly three out of four medalist foreign large-cap ..... Category Rank in MSCI EAFE Index Industry Star Rating Roche Holding RHHBY 36 Blend 2 Drug Mfr. Novartis NVS 30 Blend 3 Drug Mfr. HSBC
By YCharts : By Jeff Bailey Novartis' ( NVS ) generic unit, Sandoz, has in phase III clinical trials for the U.S. market so-called biosimilar drugs that would compete against original biologics with annual worldwide sales of about $34 billion. That's by far the biggest biosimilar program in the ...
Wall Street Breakfast Editors submit: Top Stories Kerry flying to Kiev as Russia threatens Ukraine. U.S. Secretary of State John Kerry was due to travel to Kiev today to "reaffirm the United States' strong support for Ukrainian sovereignty" after Russia took control of Crimea and threatened a ...
An independent committee has recommended that Roche ( OTCQX: RHHBY ) end a Phase III trial of its MetMab (Onartuzumab) lung-cancer treatment, as the drug didn't show "clinically meaningful
By Life Sciences Report : Biotech investing is a risky business, so investors should thoroughly examine a company's vital statistics before taking the plunge. That's the recommendation of Managing Director Debjit Chattopadhyay of Emerging Growth Equities, who brings a strict scientific discipline
small country, but it's home to some of the largest multinational companies in the world, including Nestle NSRGY, Roche RHHBY , Novartis NVS, and UBS UBS. Therefore, an investment in iShares Switzerland Capped Index EWL is not a bet on Switzerland
By Justin Gallagher : (Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.) The race to find the "next-generation" drug as a symptomatic or disease modification ...
By Peter Geschek : In February ramucirumab, an experimental drug from Eli Lilly ( LLY ) showed a statistically significant improvement in overall survival and progression-free survival as a second-line treatment in NSCLC (non-small cell lung cancer) patients. The Phase 3 trial compared ramucirumab